F S&P 500
5,886.50 -0.50 (-0.01%) F Dow Jones
43,485.00 -26.00 (-0.06%) F Nasdaq
20,377.50 +9.50 (+0.05%) E-mini Russell 2000 Index Futur
2,294.30 -3.40 (-0.15%) Petróleo
70.95 +0.28 (+0.40%) Oro
2,725.50 +18.00 (+0.66%)
Cartesian Therapeutics, Inc. (RNAC)
Fuera de horario:
Cartesian Therapeutics, Inc.
704 Quince Orchard Road
Gaithersburg, MD 20878
United States
617 923 1400
https://www.cartesiantherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 37
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Carsten Brunn Ph.D. | President, CEO & Director | 4.67M | N/D | 1971 |
| Mr. Blaine T. Davis | Chief Financial Officer | 2.49M | N/D | 1974 |
| Dr. Metin Kurtoglu M.D., Ph.D. | Chief Technology Officer | 398.28k | N/D | 1979 |
| Dr. Chris Jewell Ph.D. | Chief Scientific Officer | 296.85k | N/D | 1982 |
| Mr. Matthew Bartholomae J.D. | General Counsel & Secretary | N/D | N/D | N/D |
| Dr. Milos Miljkovic M.D., Ph.D. | Chief Medical Officer | N/D | N/D | 1984 |
| Dr. Emily English Ph.D. | SVP & Head of Manufacturing | N/D | N/D | 1980 |
| Mr. Yi Zhang Ph.D. | Senior Director of Technology | N/D | N/D | N/D |
Descripción
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Gestión corporativa
La calificación ISS Governance QuickScore de Cartesian Therapeutics, Inc. a partir del 1 de octubre de 2024 es 10. Las puntuaciones principales son Auditoría: 10; Junta: 7; Derechos del accionista: 8; Compensación: 10.
